PEPG vs PFE vs BMY vs BIIB

For growth investors, Biogen Inc.

(BIIB) is the stronger pick with 1. 4% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate PepGen Inc. (PEPG) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus Biogen Inc. at 21. 7x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x.

Over the past 5 years, Bristol-Myers Squibb Company (BMY) delivered a total return of +5.

2%, compared to -86. 1% for PepGen Inc. (PEPG). Over 10 years, the gap is even starker: PFE returned +29. 6% versus PEPG's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PepGen Inc.

(PEPG) is the lower-risk stock at 0. 17β versus Biogen Inc. 's 0. 64β — meaning BIIB is approximately 270% more volatile than PEPG relative to the S&P 500. On balance sheet safety, PepGen Inc. (PEPG) carries a lower debt/equity ratio of 12% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Biogen Inc.

(BIIB) is pulling ahead at 1. 4% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -21. 1% for Biogen Inc.. Over a 3-year CAGR, BMY leads at 1. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus 0. 0% for PepGen Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus 0. 0% for PEPG. At the gross margin level — before operating expenses — BIIB leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.

9x forward P/E versus 13. 0x for Biogen Inc. — 4. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PEPG: 291. 1% to $7. 00.

In this comparison, PFE (6.

5% yield), BMY (4. 4% yield) pay a dividend. PEPG, BIIB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

50), 4. 4% yield). Both have compounded well over 10 years (BMY: +6. 7%, BIIB: -29. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PEPG is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock; BMY is a mid-cap deep-value stock; BIIB is a mid-cap quality compounder stock. PFE, BMY pay a dividend while PEPG, BIIB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.